Evaluation of Motor Imagery, Cognitive Function and Reaction Time in Children With Bronchiectasis
Key facts
- Who runs it
- Atlas University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 40 people enrolled
- Started
- 5 Sept 2023
- Ended
- 1 Jan 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Demographic Data
- Disease History
- Pulmonary Function Test
- Reaction Time
- Functional Capacity
- Dyspnea Perception
- Quality of Life
- Fear of movement
- Ability of Motor Imagery
- Cognitive Functions
- Record updated
- 8 October 2024
Who can take part
- Age
- 7 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Diagnosed with cystic or non-cystic bronchiectasis
- Being clinically stable
- Not having an exacerbation or infection
- Being between the ages of 7-18
- To be able to read and understand Turkish
Who cannot take part
- Unstable concomitant cardiac, orthopedic or neurologic disease
- History of previous lung or liver transplantation
- History of acute exacerbation and/or hospitalization in the last 1 month
- Changes in medical treatment during the study period
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study was to evaluate motor imagery ability, reaction time and cognitive function parameters in children with CF and non-CF bronchiectasis compared to healthy peers.
The 2 groups in the trial
- Children with Bronchiectasis Experiment Group
Children with bronchiectasis Participants will be required to sign an informed consent form before the evaluation. Assesment Methods: 1. Demographic data will be collected verbally. 2. The number of exacerbations in the last 1 year, hospitalization and medications used will be questioned. 3. Pulmonary Function Test will be applied. 4. Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test. 5. Functional capacity of the patient will be evaluated with the 6 Minute Walk Test. 6. Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea. 7. Quality of life will be assessed with the "Quality of Life Scale for Children". 8. Fear of movement will be assessed with the Tampa Kinesiophobia Scale. 9. Motor Imagery ability will be assessed with the Movement Imagery Questionnaire-3, Vividness of Movement Imagery. 10. Cognitive functions will be assessed with Trail Making Test and Stroop Test.
Treatment: Demographic Data, Disease History, Pulmonary Function Test, Reaction Time, Functional Capacity, Dyspnea Perception, Quality of Life, Fear of movement, Ability of Motor Imagery, and Cognitive Functions
- Healthy Controls
Healthy Peers Participants will be required to sign an informed consent form before the evaluation. Assessment Methods: 1. Demographic data (age, height, weight, BMI) will be collected verbally via the assessment form. 2. Pulmonary Function Test will be applied. 3. Reaction time will be evaluated with the Nelson Hand-Foot Reaction Test. 4. Functional capacity of the patient will be evaluated with the 6 Minute Walk Test. 5. Dalhousie Dyspnea and Perceived Exertion Scale will be used to determine the level of dyspnea. 6. Quality of life will be assessed with the "Quality of Life Scale for Children". 7. Fear of movement will be assessed with the Tampa Kinesiophobia Scale. 8. Motor Imagery ability will be assessed with the Movement Imagery Questionnaire-3, Vividness of Movement Imagery. 9. Cognitive functions will be assessed with Trail Making Test and Stroop Test.
Treatment: Demographic Data, Pulmonary Function Test, Reaction Time, Functional Capacity, Dyspnea Perception, Quality of Life, Fear of movement, Ability of Motor Imagery, and Cognitive Functions
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 8 October 2024